Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in ...

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...

Gilead To Supply Lenacapavir For People In Low- And Lower-middle-income Countries July 09, 2025 — 08:15 am EDT Written by RTTNews.com for RTTNews -> ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a “Buy” rating on the company’s stock, retaining a ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids ...